The United Kingdom and the United States have established a major trade agreement that will guarantee no levies on UK medicine shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase expenditure on pharmaceuticals through the NHS. This commitment guarantees that duties on these vital exports will remain at zero for a period of three years.
This deal is in response to earlier statements to hike import taxes on branded drug products, with increases discussed as high as one hundred percent.
"This arrangement between the Britain bolsters the global environment for new treatments and introduces much-needed fairness to transatlantic drug exports," a statement said.
Trade Impact
Medicines constitute one of the the United Kingdom's most significant exports to the US, which is by far the primary market for major UK drugmakers.
Trade data reveal that in the 12 months prior to the third quarter, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This agreement safeguards work, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The pact involves several notable changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to prevent overspending will be restricted at 15%. In the past, refunds were more than 20%.
Recent Tensions
The deal follows a long-running tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were exacerbated by assertions that American patients were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
